Cheng Derrick L, Greenberg Paul B, Borton David A
a Alpert Medical School , Brown University , Providence , RI , USA.
b Section of Ophthalmology , Providence VA Medical Center , Providence , RI , USA.
Curr Eye Res. 2017 Mar;42(3):334-347. doi: 10.1080/02713683.2016.1270326. Epub 2017 Feb 26.
To date, reviews of retinal prostheses have focused primarily on devices undergoing human trials in the Western Hemisphere and fail to capture significant advances in materials and engineering research in countries such as Japan and Korea, as well as projects in early stages of development. To address these gaps, this systematic review examines worldwide advances in retinal prosthetic research, evaluates engineering characteristics and clinical progress of contemporary device initiatives, and identifies potential directions for future research in the field of retinal prosthetics.
A literature search using PubMed, Google Scholar, and IEEExplore was conducted following the PRISMA Guidelines for Systematic Review. Inclusion criteria were peer-reviewed papers demonstrating progress in human or animal trials and papers discussing the prosthetic engineering design. For each initiative, a description of the device, its engineering considerations, and recent clinical results were provided.
Ten prosthetic initiatives met our inclusion criteria and were organized by stimulation location. Of these initiatives, four have recently completed human trials, three are undergoing multi- or single-center human trials, and three are undergoing preclinical animal testing. Only the Argus II (FDA 2013, CE 2011) has obtained FDA approval for use in the United States; the Alpha-IMS (CE 2013) has achieved the highest visual acuity using a Landolt-C test to date and is the only device presently undergoing a multicenter clinical trial.
Several distinct approaches to retinal stimulation have been successful in eliciting visual precepts in animals and/or humans. However, many clinical needs are still not met and engineering challenges must be addressed before a retinal prosthesis with the capability to fully and safely restore functional vision can be realized.
迄今为止,关于视网膜假体的综述主要集中在西半球正在进行人体试验的设备上,未能涵盖日本和韩国等国家在材料和工程研究方面取得的重大进展,以及处于早期开发阶段的项目。为了填补这些空白,本系统综述考察了全球视网膜假体研究的进展,评估了当代设备项目的工程特性和临床进展,并确定了视网膜假体领域未来研究的潜在方向。
按照系统综述的PRISMA指南,使用PubMed、谷歌学术和IEEExplore进行文献检索。纳入标准为证明在人体或动物试验中取得进展的同行评审论文,以及讨论假体工程设计的论文。对于每个项目,提供了设备描述、其工程考量因素和近期临床结果。
有10个假体项目符合我们的纳入标准,并按刺激部位进行了分类。在这些项目中,有4个最近完成了人体试验,3个正在进行多中心或单中心人体试验,3个正在进行临床前动物试验。只有阿格斯II型(2013年获得美国食品药品监督管理局批准,2011年获得欧盟CE认证)在美国获得了食品药品监督管理局的使用批准;迄今为止,阿尔法-IMS型(2013年获得欧盟CE认证)使用兰多尔特C形视力表测试达到了最高视力,并且是目前唯一正在进行多中心临床试验的设备。
几种不同的视网膜刺激方法已成功地在动物和/或人类中引发视觉感知。然而,许多临床需求仍未得到满足,在能够完全且安全地恢复功能性视力的视网膜假体实现之前,必须应对工程方面的挑战。